AVBP — ArriVent BioPharma, Inc. stock price, charts and financials

Latest market price

28.36

+0.71+2.57%

Overview Short InterestFilings

AVBPQT70ArriVent BioPharma, Inc.·NASDAQ

Overview Short InterestFilings

28.36+2.57%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MESO+3.19%$14.87 FTRE+1.55%$20.28 NKTR+1.45%$68.36 GHRS+3.50%$28.72 RAPP+1.35%$41.95 AGIO+2.00%$33.61 ZBIO-1.08%$31.97 GPCR-1.13%$35.10

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	22.41%	Shs Outstand	46.57M	Perf Week	-1.18%

Market Cap	1.32B	Forward P/E	-	EPS next Y	-3.78	Insider Trans	0.00%	Shs Float	29.78M	Perf Month	-5.47%

Enterprise Value	1.01B	PEG	-	EPS next Q	-1.07	Inst Own	-	Short Float	29.19%	Perf Quarter	-9.57%

Income	-166.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	16.15	Perf Half Y	24.33%

Sales	0.00	P/B	4.30	EPS next Y	10.59%	ROA	-41.48%	Short Interest	8.69M	Perf YTD	40.95%

Book/sh	6.59	P/C	4.22	EPS next 5Y	-	ROE	-50.26%	52W High	35.83 -20.85%	Perf Year	55.82%

Cash/sh	6.72	P/FCF	-	EPS past 3/5Y	-	ROIC	-47.92%	52W Low	17.00 66.82%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	3.64% 4.10%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-41.41%	Oper. Margin	0.00%	ATR (14)	1.30	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	14.16	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	41.09	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	14.16	EPS Q/Q	-16.67%	SMA20	-4.39%	Beta	1.31	Target Price	46.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-6.86%	Rel Volume	0.86	Prev Close	27.65

Employees	77	LT Debt/Eq	-	Earnings	Nov 16	SMA200	4.98%	Avg Volume	529.93K	Price	28.36

IPO Date	Jan 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.35% -	Net Debt/EBITDA	0.94	Volume	456,428	Change	2.57%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-17-26	Reiterated	HC Wainwright & Co.	Buy	$36 → $47
May-29-26	Reiterated	Truist Securities	Buy	$43 → $45
Dec-10-25	Initiated	BTIG on firmonertinib potential	Buy	$45
Nov-25-25	Initiated	Truist	Buy	$43
Jul-10-25	Resumed	Goldman Sachs	Buy	$33
Sep-10-24	Reiterated	HC Wainwright & Co.	Buy	$30 → $36
Aug-16-24	Reiterated	HC Wainwright & Co.	Buy	$30
Jul-22-24	Reiterated	Oppenheimer		$35

Latest News· Times ET

Aug-30-26

Aug-30-2612:14AM

Deutsche Bank AG Acquires Shares of 39,180 ArriVent BioPharma, Inc. $AVBPdefenseworld.net

Aug-27-26

Aug-27-2612:00AM

ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside CaseSeekingAlpha

Aug-26-26

Aug-26-2610:16PM

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of “Moderate Buy” from Analystsdefenseworld.net

Aug-17-26

Aug-17-2605:01AM

Veeva Systems To Rally Around 13%? Here Are 10 Top Analyst Forecasts For MondayBenzinga

Aug-12-26

Aug-12-2611:47PM

Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBPdefenseworld.net

12:17PM

ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) EstimateBenzinga

12:01PM

ArriVent BioPharma Reports Second Quarter 2026 Financial Resultsglobenewswire.com

Jul-25-26

Jul-25-2612:05AM

Affinity Asset Advisors LLC Purchases 25,000 Shares of ArriVent BioPharma, Inc. $AVBPdefenseworld.net

Company

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021
Total Revenue	0	0	0	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—
Gross Profit	0	0	0	—	—
Selling, General and Administrative Excl. Other	24	15	10	—	—
Research and Development	153	79	65	—	—
Other Operating Expense	1	0	0	—	—
Operating Income	-178	-94	-75	—	—
Interest Expense	0	0	0	—	—
Unusual Expense	—	—	—	—	—
Non-Operating Income (Expense)	11	14	5	—	—
Net Income Before Taxes	-166	-80	-69	—	—
Income Taxes	0	0	0	—	—
Consolidated Net Income	-166	-80	-69	—	—
Net Income From Continuing Operations	-166	-80	-69	—	—
Net Income	-166	-80	-69	—	—
EPS (Recurring)	-4.32	-2.56	-2.17	—	—
EPS (Basic, Before Extraordinaries)	-4.32	-2.56	-2.17	—	—
EPS (Diluted)	-4.32	-2.56	-2.17	—	—
EBITDA	-166	-80	-69	—	—
Other After Tax Adjustments	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—
Gross Margin	—	—	—	—	—
Operating Margin	—	—	—	—	—
Net Margin	—	—	—	—	—
Shares Outstanding	38	31	32	—	—
Market Capitalization	765	826	—	—	—
Operating Lease Expense	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HILLHOUSE INVESTMENT MANAGEMENT, LTD.	10% Owner	Dec 10 '25	Sale	23.37	555,555	12,983,320	3,929,117	Feb 03
LaChapelle Robin	Chief Operating Officer	Jul 11 '25	Option Exercise	2.28	11,153	25,429	135,736	Jul 15
LaChapelle Robin	Chief Operating Officer	Sep 19 '24	Option Exercise	3.28	27,566	90,482	124,583	Sep 23
HILLHOUSE INVESTMENT MANAGEMENT, LTD.	10% Owner	Jan 30 '24	Buy	18.00	555,555	9,999,990	4,484,672	Feb 01
ORBIMED ADVISORS LLC	director, 10 percent owner:	Jan 30 '24	Buy	18.00	222,222	3,999,996	1,513,664	Jan 31
GORDON CARL L	director, 10 percent owner:	Jan 30 '24	Buy	18.00	222,222	3,999,996	1,513,664	Jan 31
HEALY JAMES	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,696,752	Jan 31

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.